Addressing the question of cross-resistance, we generated vemurafenib resistant BRAFV600E cells by chronic exposure of melanoma cells to the serine/threonine-protein kinase B-Raf inhibitor vemurafenib. This evidence concerns the gene BRAF and melanoma.